These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29684427)

  • 1. Relationship between the frequency of influenza vaccination and cell-mediated immunity.
    Otani N; Shima M; Ueda T; Ichiki K; Nakajima K; Takesue Y; Honjo K; Yoshida N; Kawata S; Okuno T
    J Immunol Methods; 2018 Jul; 458():58-62. PubMed ID: 29684427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of influenza vaccine-induced cell-mediated immunity: Comparison between methods using peripheral blood mononuclear cells and whole blood.
    Otani N; Shima M; Ueda T; Ichiki K; Nakajima K; Takesue Y; Okuno T
    Microbiol Immunol; 2019 Jun; 63(6):223-228. PubMed ID: 31070266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of influenza vaccine-immunogenicity in cell-mediated immunity.
    Otani N; Shima M; Ueda T; Ichiki K; Nakajima K; Takesue Y; Okuno T
    Cell Immunol; 2016 Dec; 310():165-169. PubMed ID: 27665371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
    Hanitsch LG; Löbel M; Mieves JF; Bauer S; Babel N; Schweiger B; Wittke K; Grabowski P; Volk HD; Scheibenbogen C
    Vaccine; 2016 May; 34(21):2417-2423. PubMed ID: 27055021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season.
    Puig-Barberà J; Guglieri-López B; Tortajada-Girbés M; López-Labrador FX; Carballido-Fernández M; Mollar-Maseres J; Schwarz-Chavarri G; Baselga-Moreno V; Mira-Iglesias A; Díez-Domingo J;
    Vaccine; 2017 Dec; 35(52):7331-7338. PubMed ID: 29128380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y
    J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.
    Ambati A; Einarsdottir S; Magalhaes I; Poiret T; Bodenstein R; LeBlanc K; Brune M; Maeurer M; Ljungman P
    Transpl Infect Dis; 2015 Jun; 17(3):371-9. PubMed ID: 25817044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
    Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
    Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.
    Schmidt T; Dirks J; Enders M; Gärtner BC; Uhlmann-Schiffler H; Sester U; Sester M
    Eur J Immunol; 2012 Jul; 42(7):1755-66. PubMed ID: 22585549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay J; Fonseca K; Charest H; Krajden M; Petric M; Mahmud SM; Van Caeseele P; Bastien N; Eshaghi A; Li Y
    J Infect Dis; 2015 Sep; 212(5):726-39. PubMed ID: 25784728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors.
    Kang CK; Kim HR; Song KH; Keam B; Choi SJ; Choe PG; Kim ES; Kim NJ; Kim YJ; Park WB; Kim HB; Oh MD
    J Infect Dis; 2020 Nov; 222(11):1902-1909. PubMed ID: 32479600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.